Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1975 Aug;37(8):861–867. doi: 10.1136/hrt.37.8.861

Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome.

R A Spurrell, C W Thorburn, J Camm, E Sowton, D C Deuchar
PMCID: PMC482887  PMID: 53057

Abstract

Seven patients with normal specialized conduction system and three patients with the Wolff-Parkinson-White (WPW) syndrome were studied using programmed stimulation of the heart before and after the administration of intravenous disopyramide. The principal effect of this drug was to prolong the effective refractory period of the atria and ventricles, and to prolong the effective refractory period of the anomalous pathway in the WPW syndrome. In addition, it prolonged the conduction time in the anomalous pathway in the WPW syndrome. These findings suggest that disopyramide would be a useful and safe drug in the management of certain atrial and ventricular arrhythmias and in the management of the Wolff-Parkinson-White syndrome with atrial fibrillation.

Full text

PDF
861

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Damato A. N., Lau S. H. Clinical value of the electrogram of the conduction system. Prog Cardiovasc Dis. 1970 Sep;13(2):119–140. doi: 10.1016/0033-0620(70)90005-8. [DOI] [PubMed] [Google Scholar]
  2. Dreifus L. S., Haiat R., Watanabe Y., Arriaga J., Reitman N. Ventricular fibrillation. A possible mechanism of sudden death in patients and Wolff-Parkinson-White syndrome. Circulation. 1971 Apr;43(4):520–527. doi: 10.1161/01.cir.43.4.520. [DOI] [PubMed] [Google Scholar]
  3. Härtel G., Louhija A., Konttinen A. Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Ther. 1974 Jun;15(6):551–555. doi: 10.1002/cpt1974156551. [DOI] [PubMed] [Google Scholar]
  4. Josephson M. E., Caracta A. R., Lau S. H., Gallagher J. J., Damato A. N. Electrophysiological evaluation of disopyramide in man. Am Heart J. 1973 Dec;86(6):771–780. doi: 10.1016/0002-8703(73)90280-9. [DOI] [PubMed] [Google Scholar]
  5. KATZ M. J., MEYER C. E., EL-ETR A., SLODKI S. J. Clinical evaluation of a new anti-arrhythmic agent, SC-7031. Curr Ther Res Clin Exp. 1963 Jul;5:343–350. [PubMed] [Google Scholar]
  6. Scherlag B. J., Lau S. H., Helfant R. H., Berkowitz W. D., Stein E., Damato A. N. Catheter technique for recording His bundle activity in man. Circulation. 1969 Jan;39(1):13–18. doi: 10.1161/01.cir.39.1.13. [DOI] [PubMed] [Google Scholar]
  7. Spurrell R. A., Sowton E., Deuchar D. C. Ventricular tachycardia in 4 patients evaluated by programmed electrical stimulation of heart and treated in 2 patients by surgical division of anterior radiation of left bundle-branch. Br Heart J. 1973 Oct;35(10):1014–1025. doi: 10.1136/hrt.35.10.1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Vismara L. A., Mason D. T., Amsterdam E. A. Disopyramide phosphate: clinical efficacy of a new oral antiarrhythmic drug. Clin Pharmacol Ther. 1974 Aug;16(2):330–335. doi: 10.1002/cpt1974162330. [DOI] [PubMed] [Google Scholar]
  9. Wellens H. J., Durrer D. Effect of digitalis on atrioventricular conduction and circus-movement tachycardias in patients with Wolff-Parkinson-White syndrome. Circulation. 1973 Jun;47(6):1229–1233. doi: 10.1161/01.cir.47.6.1229. [DOI] [PubMed] [Google Scholar]
  10. Wellens H. J., Durrer D. Patterns of ventriculo-atrial conduction in the Wolff-Parkinson-White syndrome. Circulation. 1974 Jan;49(1):22–31. doi: 10.1161/01.cir.49.1.22. [DOI] [PubMed] [Google Scholar]
  11. Wellens H. J., Schuilenburg R. M., Durrer D. Electrical stimulation of the heart in patients with ventricular tachycardia. Circulation. 1972 Aug;46(2):216–226. doi: 10.1161/01.cir.46.2.216. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES